For tumor diagnosis, the commonly used clinical methods in China include tumor marker detection, imaging (B-ultrasonic, CT, MRI, PET-CT), pathological detection, risk gene detection and circulating tumor cell detection in recent years. However, these methods have the disadvantages of poor sensitivity, low specificity, invasive injury and radiation injury, which leads to limited clinical effect and poor compliance of the subjects.For malignant tumors, early detection and early treatment can effectively improve survival.In recent years, with the development of molecular biology and immunology, the diagnosis and treatment of tumor has risen to the level of antigen epitope peptide. More specific, more accurate and more convenient methods of tumor detection are becoming the main direction of tumor diagnosis.

As a leader in cancer precision medicine，.Bio-High relies on "The Nobel Prize Workstation" to build “early screening + tumor Auxiliary Diagnosis Guidance+ individualized treatment”new model of health management, .Bio-High complete the transformation at “Stanford University Translational Medicine Center · Bio-High Technology Joint Research and Development Centre”and launch of “Specific Multi-Target Cellular Immunotherapy Technology System of Tumor Disease Categories”, the technique is an accurate tumor screening technique by collecting 5ml of peripheral blood from patients, the number and types of positive targets in cancer patients were detected by using the fluid-based platform and the specific target library. It is a "sharp weapon" for the early detection of tumor, and also a reference for the clinical diagnosis of tumor. It is also the only way to realize the individualized and accurate treatment of tumor.